📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. The control strategy — the planned set of controls that assure the product consistently meets its quality attributes.

Why it exists. A control strategy links raw materials, process parameters, and in-process and release tests to the CQAs, so quality is built in rather than only tested at the end (ICH Q8-Q11).

How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.

Format & governing standard. ICH Q8(R2) · Q9(R1) · Q10 · Q11 · Q12

Control Strategy — GLPI-103

Field	Value
Document ID	M3-CS
Version	2.0 (expanded)
Standard	ICH Q8(R2) · Q9(R1) · Q10 · Q11 · Q12
Confidentiality	Confidential

[MOCK — deep-knowledge assumption] Integrated control strategy linking the CQAs (M3-QTPP) to material/process controls and release/stability specifications across the lifecycle.

Change History

Version	Date	Author	Summary
1.0	2026-06-29	CMC	Initial control strategy
2.0	2026-06-30	CMC	Expanded — five control elements, CPP target ranges, IPCs, analytical and lifecycle control

1. Control-Strategy Framework

A holistic, risk-based control strategy (ICH Q10) assures each CQA (M3-QTPP §2) through five complementary elements: (1) input-material controls, (2) process design + critical-process-parameter (CPP) control, (3) in-process controls (IPCs), (4) release & stability specifications, and (5) procedural/facility (GMP) controls. CPPs and proven acceptable ranges were established by quality risk management (ICH Q9; FMEA) and design-of-experiments characterisation.

2. Drug Substance — CPP / IPC Map

Step	CPP / IPC (target)	CQA assured
SPPS coupling	coupling completion (free amine ≤0.5%); reagent equivalents; temperature	sequence fidelity → deletion impurities
Side-chain lipidation	orthogonal deprotection completeness; acylation completion	des-lipid impurity
Cleavage / deprotection	scavenger composition; time/temperature	side-chain integrity, related substances
Preparative RP-HPLC	gradient, load factor, pooling criterion (purity ≥95%, single max ≤1.0%)	related substances, des-lipid, aggregates
Salt exchange	acetate buffer, residual TFA endpoint	counter-ion, residual TFA
Lyophilisation	shelf temperature, vacuum, endpoint	water content, stability

3. Drug Product — Control Map

Product	Step	CPP / IPC (target)	CQA assured
IV	compounding	bulk pH 7.2–7.6; pre-filtration bioburden ≤10 CFU/100 mL	assay, stability, sterility assurance
IV	sterile filtration	filter integrity (pre/post bubble-point); redundant 0.22 µm	sterility
IV	aseptic fill	fill weight, environmental monitoring, media-fill validation	sterility, extractable volume
Oral	blending	blend uniformity (RSD ≤5%)	content uniformity
Oral	compression	compression force → hardness, friability, disintegration	dissolution, content uniformity

4. Analytical Control Strategy

Release and stability specifications (M3-S §S.4; M3-P §P.5) employ stability-indicating RP-HPLC (assay/related substances), SE-HPLC (aggregates), functional bioassays (GLP-1R/APJ potency), and compendial sterility/endotoxin/particulate tests; all methods validated per ICH Q2(R2) (M3-AMV). The strategy balances end-product testing with upstream control of CQAs that cannot be fully assured at release (e.g., sterility assurance, aggregation propensity).

5. Lifecycle Management (Q10 / Q12)

Continued process verification (CPV) monitors CPPs/CQAs across commercial production; change management and the defined Established Conditions (ICH Q12) govern post-approval changes with appropriate reporting categories; an ongoing/commitment stability programme (M3-STAB) and the Product Quality Review maintain the validated state.